Committee Chair Patty Murray (D-WA) (Graeme Sloan/Sipa USA)(Sipa via AP Images)

Sen­a­tors grill in­dus­try groups over FDA user fee agree­ments to fund the agency through 2027

Mem­bers of the Sen­ate health com­mit­tee on Tues­day fired off ques­tions at drug in­dus­try reps in the first of two hear­ings to deal with the lat­est five-year fund­ing agree­ments that Con­gress has to re-au­tho­rize by the end of Sep­tem­ber and that the FDA re­lies on to re­view new drug, gener­ic drug, bi­o­log­ic and biosim­i­lar ap­pli­ca­tions.

Com­mit­tee Chair Pat­ty Mur­ray (D-WA) made clear in her open­ing re­marks that the FDA has done a su­pe­ri­or job, par­tic­u­lar­ly when it’s come to the pan­dem­ic, liv­ing up to its “gold stan­dard” tagline, but “FDA doesn’t run on grat­i­tude.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.